Garry Pairaudeau

Direttore Tecnico/Scientifico/R&S presso Exscientia AI Ltd.

58 anni

Health Technology

Consumer Services

Profilo

Garry Pairaudeau is currently the Chief Technology Officer at Exscientia AI Ltd.
He previously worked at AstraZeneca PLC as the Head-Hit Discovery from 2017 to 2020.
He also worked as the Chief Technology Officer at Exscientia Plc from 2020 to 2023.
Dr. Pairaudeau received his undergraduate and doctorate degrees from The University of Southampton.

Posizioni attive di Garry Pairaudeau

Società	Posizione	Inizio
Exscientia AI Ltd. Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom.	Direttore Tecnico/Scientifico/R&S	01/11/2020

Tutte le posizioni attive di Garry Pairaudeau

Precedenti posizioni note di Garry Pairaudeau

Società	Posizione	Fine
EXSCIENTIA PLC	Direttore Tecnico/Scientifico/R&S	30/06/2023
ASTRAZENECA PLC	Corporate Officer/Principal	01/11/2020

Vedi nel dettaglio l'esperienza di Garry Pairaudeau

Formazione di Garry Pairaudeau

The University of Southampton

Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Garry Pairaudeau

Relazioni

100 +

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	2
EXSCIENTIA PLC	Health Technology
ASTRAZENECA PLC	Health Technology

Aziende private	1
Exscientia AI Ltd. Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom.	Health Technology